COMMUNIQUÉS West-GlobeNewswire

Vericel to Present at the 6th Annual Cell & Gene Therapy Investor Day
10/04/2018
CAMBRIDGE, Mass., April 10, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ: VCEL ), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, [...]
AGTC Announces Completion of Enrollment of Phase 1 / 2 Clinical Study of Investigational Gene Therapy in Patients with X-linked Retinoschisis (XLRS)
10/04/2018
GAINESVILLE, Fla. and CAMBRIDGE, Mass., April 10, 2018 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ: AGTC ), a biotechnology company conducting human clinical trials of adeno-associated virus ( [...]
ProLynx announces allowance of additional U.S. patent for PLX038, a novel DNA damage response enhancer
10/04/2018
SAN FRANCISCO, April 10, 2018 (GLOBE NEWSWIRE) -- Prolynx LLC (San Francisco, CA) announced it received a Notice of Allowance for its DNA damage enhancer PLX038 (PEG~SN-38), currently in Phase 1 trials at MD Anderson. [...]
Patient Home Monitoring Announces Plans to Change Name to Protech Home Medical; Launches New Investor Website
10/04/2018
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN. CINCINNATI, April 10, 2018 (GLOBE NEWSWIRE) -- Patient Home [...]
Loop Industries Appoints Laurence Sellyn to Board of Directors
10/04/2018
MONTREAL, April 10, 2018 (GLOBE NEWSWIRE) -- Loop Industries, Inc. (NASDAQ: LOOP ) today announced the appointment of Laurence Sellyn to the Board of Directors, effective immediately. Mr. Sellyn has assumed the role of [...]
BLVD Centers Announces Weedaide™ is Available for Preorder in Advance of Product Launch
10/04/2018
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES LOS ANGELES, April 10, 2018 (GLOBE NEWSWIRE) -- BLVD Centers Corporation (“ BLVD ” or the “ Company ”) (TSXV:CXV), a [...]
Election of employee representative to Zealand's Board of Directors
10/04/2018
Company Announcement - No. 8/2018 Election of employee representative to Zealand's Board of Directors Copenhagen, April 10, 2018 - Zealand Pharma A/S ("Zealand") announces that Jens Peter Stenvang has been re-elected as [...]
Assure Holdings Appoints Kent J. Lund to its Board of Directors
10/04/2018
- Lund Brings Assure Nearly 20 Years of Experience in Legal and Financial Services Securities Compliance - PARKER, Colo., April 10, 2018 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the “Company” or “Assure”) (TSXV:IOM) ( [...]
International Stem Cell Corporation Announces 2017 Fourth Quarter and Year-End Results
10/04/2018
CARLSBAD, Calif., April 10, 2018 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO) ( www.internationalstemcell.com ) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company [...]
BriaCell to Present Encouraging Clinical Data at AACR 2018
10/04/2018
- Early Evidence of Safety and Impressive Anti-Tumor Activity of Bria-IMT™ - BERKELEY, Calif. and VANCOUVER, British Columbia, April 10, 2018 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell") (TSX-V: BCT ) ( [...]
Agritek Holdings Inc. Provides Update to Shareholders and Announces Approval and Renewal of Uplisting on OTCQB for 2018 and Filing of 10K Annual Report Within Extension Period
10/04/2018
LOS ANGELES, CA, April 10, 2018 (GLOBE NEWSWIRE) -- Agritek Holdings, Inc. (OTCQB: AGTK) www.AgritekHoldings.com , a fully integrated, active real estate investor for the cannabis sector and consultant for multiple [...]
Spring Bank Announces Expanded Inarigivir Data from the ACHIEVE Trial to Be Presented at The International Liver Congress™
10/04/2018
*Results from full 24 weeks of dosing from the first two cohorts of Part A in the ongoing Phase 2 ACHIEVE trial in hepatitis B to be highlighted in oral and poster presentations *30% of patients in first two cohorts [...]
Achaogen Announces Multiple Plazomicin Presentations at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
10/04/2018
-- Study findings support the potential for plazomicin to address difficult-to-treat infections, including those caused by carbapenem-resistant Enterobacteriaceae -- SOUTH SAN FRANCISCO, Calif., April 10, 2018 (GLOBE [...]
VBL Therapeutics to Present Late-Breaking Research at the American Association for Cancer Research (AACR) 2018 Annual Meeting on April 16
10/04/2018
TEL AVIV, Israel, April 10, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for [...]
CareDx Launches HeartCare® for Heart Transplant Recipients
10/04/2018
HeartCare combines AlloMap and AlloSure-Heart for Comprehensive Rejection Surveillance BRISBANE, Calif., April 10, 2018 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ: CDNA ), a molecular diagnostics company focused on the [...]
ReNetX Bio Invited to Present Breakthrough at Leading Spinal Cord Injury Symposium
10/04/2018
NEW HAVEN, Conn., April 10, 2018 (GLOBE NEWSWIRE) -- Thanks to the promise of its NoGo Trap therapeutic for treating chronic spinal cord injury (SCI), New Haven-based startup ReNetX Bio has been invited to present as [...]
Caladrius Biosciences Receives SAKIGAKE Expedited Review Designation in Japan for CLBS12 for Treating Critical Limb Ischemia
10/04/2018
BASKING RIDGE, N.J., April 10, 2018 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS ) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple technology platforms [...]
Fibrocell to Present at 6th Annual Cell & Gene Therapy Investor Day and 2018 World Orphan Drug Congress USA
10/04/2018
EXTON, Pa., April 10, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ: FCSC ), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today [...]
Selecta Biosciences Presents Positive New Data from Ongoing Phase 2 Trial of SEL-212, in Development for Chronic Severe Gout, at PANLAR 2018 Congress
10/04/2018
3-month Phase 2 data indicate SEL-212 (SVP-Rapamycin + pegsiticase) product profile may provide better and more sustained serum uric acid control, fewer flares, and less frequent dosing compared with recent data [...]

Pages